Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 12, 2026JAMA Neurology

Management of Exacerbations and Rescue Therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

RNRichard J. NowakKUKimiaki UtsugisawaMBMichael Benatar

Discussion

Loading...

Member takes

Overview

Randomized trial examines ineebilizumab's effect on exacerbations and rescue therapy in myasthenia gravis, suggesting improved outcomes.

Key Points

  • To evaluate the impact of inebilizumab on exacerbations and rescue therapy use in myasthenia gravis patients.
  • Phase 3, international, randomized, placebo-controlled trial (MINT)
  • Participants with AChR+ and MuSK+ myasthenia gravis were enrolled between August 2020 and November 2023
  • Randomization 1:1 to inebilizumab or placebo with corticosteroid tapering to 5 mg or less.
  • Inebilizumab reduced exacerbation risk at week 26 (HR 0.41, 95% CI 0.24-0.70)
  • In the AChR+ subpopulation, a risk reduction was observed at week 52 (HR 0.39, 95% CI 0.23-0.68)
  • For the MuSK+ subpopulation, a significant reduction was noted by week 26 (HR 0.21, 95% CI 0.06-0.79).

Cite This Study

Nowak et al. (2026) studied this question.

synapsesocial.com/papers/6a7c3d1906a85aed514b7c1fhttps://doi.org/10.1001/jamaneurol.2026.2558
View Full Paper
Ask AI
Bookmark
Share